These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 37327699)

  • 1. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
    Botta GP; Kato S; Patel H; Fanta P; Lee S; Okamura R; Kurzrock R
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors' therapeutic implication.
    Pang LL; Zhou HQ; Zhang YX; Zhuang WT; Pang F; Chen LJ; Liao J; Huang YH; Mao TQ; Mai ZH; Zhang L; Fang WF
    ESMO Open; 2024 Jun; 9(6):103472. PubMed ID: 38833972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.
    Sun M; Gu Y; Fang H; Shao F; Lin C; Zhang H; Li H; He H; Li R; Wang J; Liu H; Xu J
    Cancer Sci; 2024 Mar; 115(3):905-915. PubMed ID: 38148578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The stage-dependent prognostic role of
    Zhou H; Sun D; Miao C; Tao J; Ge C; Chen T; Li H; Hou H
    Transl Cancer Res; 2023 Nov; 12(11):3088-3104. PubMed ID: 38130310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic mapping of metastatic organotropism in lung adenocarcinoma.
    Lengel HB; Mastrogiacomo B; Connolly JG; Tan KS; Liu Y; Fick CN; Dunne EG; He D; Lankadasari MB; Satravada BA; Sun Y; Kundra R; Fong C; Smith S; Riely GJ; Rudin CM; Gomez DR; Solit DB; Berger MF; Li BT; Mayo MW; Matei I; Lyden DC; Adusumilli PS; Schultz N; Sanchez-Vega F; Jones DR
    Cancer Cell; 2023 May; 41(5):970-985.e3. PubMed ID: 37084736
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Wang Y; Meraz IM; Qudratullah M; Kotagiri S; Han Y; Xi Y; Wang J; Lissanu Y
    bioRxiv; 2024 Jun; ():. PubMed ID: 38948751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of AT-rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives.
    Zhang X; Zhang Y; Zhang Q; Lu M; Chen Y; Zhang X; Zhang P
    J Cell Mol Med; 2023 Dec; 28(5):e18063. PubMed ID: 38041544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
    Makarem M; Rotow JK
    J Thorac Oncol; 2023 Dec; 18(12):1615-1617. PubMed ID: 37993212
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of chromatin remodeler SMARCA4/BRG1 in brain cancers: a potential therapeutic target.
    Navickas SM; Giles KA; Brettingham-Moore KH; Taberlay PC
    Oncogene; 2023 Jul; 42(31):2363-2373. PubMed ID: 37433987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy.
    Soto-Castillo JJ; Llavata-Marti L; Fort-Culillas R; Andreu-Cobo P; Moreno R; Codony C; García Del Muro X; Alemany R; Piulats JM; Martin-Liberal J
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: SMARCA4 (BRG1)-deficient undifferentiated carcinoma of gallbladder with genetic analysis.
    Meng X; Ma J; Meng N; Yun T; Niu B
    Front Oncol; 2023; 13():1086266. PubMed ID: 37456262
    [No Abstract]   [Full Text] [Related]  

  • 12. Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy.
    Shi Y; Shin DS
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
    Gosney JR; Paz-Ares L; Jänne P; Kerr KM; Leighl NB; Lozano MD; Malapelle U; Mok T; Sheffield BS; Tufman A; Wistuba II; Peters S
    ESMO Open; 2023 Aug; 8(4):101587. PubMed ID: 37356358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of glycogen phosphorylase L as a potential target for lung cancer.
    He XL; Lyu WY; Li XY; Zhao H; Qi L; Lu JJ
    Med Oncol; 2023 Jun; 40(7):211. PubMed ID: 37347364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic regulation of hybrid epithelial-mesenchymal cell states in cancer.
    Sample RA; Nogueira MF; Mitra RD; Puram SV
    Oncogene; 2023 Jul; 42(29):2237-2248. PubMed ID: 37344626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational landscape of SWI/SNF complex genes reveal correlation to predictive biomarkers for immunotherapy sensitivity in lung adenocarcinoma patients.
    Xu H; Chen HC; Yang L; Yang G; Liang L; Yang Y; Tang H; Bao H; Wu X; Shao Y; An G; Wang Y
    ESMO Open; 2023 Jun; 8(3):101585. PubMed ID: 37327699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
    Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
    Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.